Showing 1 to 10 of 69 Clinical Trials
CLINICAL TRIAL Trial No ClinicalTrials.gov ID |
Principal Investigator
Coordinator |
||
---|---|---|---|
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu NCT05303493 Recruiting |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Melanoma Non Small Cells - Lung |
Dr. Bertrand Routy Wiam Belkaid 514-890-8000 |
Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu NCT05303493 Recruiting |
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE |
Melanoma Non Small Cells - Lung |
Dr. Nathalie Daaboul Marilyn Tessier 450-466-5000 poste 7691 |
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Subjects With Metastatic Solid Malignancies After Progression on Prior PD-1 Inhibitor Treatment
SGN35-033 (KEYNOTE B81) NCT04609566 Recruiting |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS |
Head and Neck Melanoma Non Small Cells - Lung |
Dr. Wilson Miller Daria Krutauz 514-340-8222 poste 24301 Rim Hojeij 514-340-8222 poste 26187 |
A Randomized Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLE-MATES Trial
STABLE-MATES Trial (JoLT-Ca) NCT02468024 Recruiting |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non Small Cells - Lung |
Dr. Édith Filion Dr. Moishe Liberman Adeline Jouquan 514-890-8000 poste 26214 |
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer
MK-3475-671 NCT03425643 Recruiting |
CIUSSS DE L'OUEST-DE-L'ILE-DE-MONTREAL
CENTRE HOSPITALIER DE ST. MARY |
Non Small Cells - Lung |
Dr. Adrian Langleben Natalia Gonzalez-Cardenas 514-345-3511 poste 5507 |
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer
MK-3475-671 NCT03425643 Recruiting |
CIUSSS DU SAGUENAY – LAC-SAINT-JEAN
HOPITAL DE CHICOUTIMI |
Non Small Cells - Lung |
Dr. Paul Bégin Nancy-Lisa Gagné 418-541-1234 poste 2707 |
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer
PACIFIC-4/RTOG-351 NCT03833154 Recruiting |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non Small Cells - Lung |
Dr. Thi Trinh Thuc Vu Diane Trudel 514-890-8000 poste 11181 |
A Randomized Phase II Trial to Assess the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy
PET-BOOST NCT02788461 Recruiting |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN |
Non Small Cells - Lung |
Dr. Sergio Faria Marianna Perna 514-934-1934 poste 43191 |
An Open-Label, Multi-Drug, Biomarker-Directed, Multi-Centre Phase II Umbrella Study in Patients With Non-Small Cell Lung Cancer, Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.
D6185C00001 (HUDSON) NCT03334617 Temporary interruption |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Non Small Cells - Lung |
Dr. Marie Florescu Francine Richard 514-890-8000 poste 24853 |
A Multicenter, Open-label, Phase 1b/2 Study To Evaluate Safety And Efficacy Of Avelumab (msb0010718c) In Combination With Chemotherapy With Or Without Other Anti-cancer Immunotherapies As First-line Treatment In Patients With Advanced Malignancies
B9991023 NCT03317496 Recruiting |
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN |
Non Small Cells - Lung |
Dr. Scott Owen Olivier Bouchereau 514-934-1934 poste 43129 |